You are here

  • Home
  • Archive
  • Volume 101, Issue 6
  • Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Responses

Article menu
Download PDFPDF
Clinical science
Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 28 March 2017
    Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
    • Dan Calugaru, Ophthalmologist Univ of Medicine Cluj-Napoca/Romania
    • Other Contributors:
      • Mihai Calugaru, Professor Univ Ophthalmology

    Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
    Dan Calugaru, Mihai Calugaru
    Department of Ophthalmology, Univ of Medicine Cluj-Napoca/Romania

    Re: Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Jeong and Sagong. Br J Ophthalmol 2016; http: /dx.doi. org/ 10.1136/bjophthalmol-2016-309144.

    Dear Editor
    We would like to address several challenges that have arisen from the study by Jeong and Sagong (1), which can be specifically summarized below.
    1. The study included a relatively small sample size of cases examined with a fairly short follow-up period.
    2. Several relevant data are missing in the study. For example, the anatomic types of macular edema (diffuse/cystic changes within neurosensory retina/subretinal/sub retinal pigment epithelium (RPE) fluid/ mixed type) at baseline and at months 3 and 6; the qualitative status of the 4 outer retinal layers (eg, the external limiting membrane band, the ellipsoid zone, the interdigitation zone, and the retinal pigment epithelial band) at presentation as well as the magnitude of changes (disruption/absence) during the study as potential predictors of visual loss/improvement after aflibercept (Eylea; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA) treatment; the percentages of patients with complete polyp regression and...

    Show More
    Conflict of Interest:
    None declared.